What's Happening?
Sanofi has decided to halt the development of its anti-OX40L antibody, amlitelimab, for the treatment of atopic dermatitis (AD). This decision follows mixed clinical data from phase 3 studies, SHORE and COAST, which did not demonstrate a significant advantage
over Dupixent, another AD treatment developed in partnership with Regeneron. Despite promising results from a long-term extension study, ESTUARY, which showed sustained clinical response in patients aged 12 and older, Sanofi concluded that the overall efficacy and safety profile of amlitelimab does not justify further development in AD. The company will now focus on other pipeline projects, including frexalimab and SAR441566, as it anticipates the potential loss of patent protection for Dupixent in the early 2030s.
Why It's Important?
Sanofi's decision to abandon amlitelimab in AD highlights the challenges pharmaceutical companies face in developing new treatments that can compete with existing market leaders. Dupixent, which generated nearly $18 billion in sales last year, remains a dominant player in the AD treatment market. The move underscores the importance of strategic pipeline management, as Sanofi shifts focus to other promising projects to maintain its competitive edge. This decision also impacts patients and healthcare providers seeking new treatment options for AD, emphasizing the need for continued innovation in addressing the diverse immune mechanisms underlying inflammatory skin conditions.
What's Next?
Sanofi plans to work closely with investigators, site teams, and regulatory authorities to wind down ongoing amlitelimab studies in AD, ensuring appropriate transition of care for enrolled patients. The company will continue to explore amlitelimab's potential in other indications, such as coeliac disease, with phase 2 trial results expected later this year. Sanofi remains committed to advancing treatments for inflammatory skin conditions and will focus on developing its other pipeline assets, frexalimab and SAR441566, to address future market needs.
